Fennec Pharmaceuticals Secures PEDMARK Exclusivity Until 2033 by Settling Generic Litigation
Summary
Fennec Pharmaceuticals announced a settlement agreement resolving patent litigation with Cipla, extending market exclusivity for its PEDMARK® product until September 1, 2033.
Key Events
-
Patent Litigation Settled
Fennec Pharmaceuticals Inc. resolved its patent litigation with Cipla Limited and Cipla USA, Inc. concerning Cipla's application to market a generic version of PEDMARK®.
-
PEDMARK Exclusivity Extended
Under the License Agreement, Cipla has agreed not to enter the U.S. market with its generic sodium thiosulfate product until September 1, 2033, subject to earlier entry under specified circumstances.
-
Protection for Key Product
PEDMARK® is the first and only FDA-approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients, with patent protection until 2039.
Analysis
This filing announces a significant legal victory for Fennec Pharmaceuticals, securing an extended period of market exclusivity for its key product, PEDMARK®. By settling the patent litigation with Cipla, the company has effectively delayed generic competition for its FDA-approved therapy until at least September 1, 2033. This agreement protects a crucial revenue stream for an additional 7.5 years, providing long-term stability and predictability for the company's flagship product, which is the only FDA-approved therapy for reducing ototoxicity in pediatric cancer patients.
At the time of this filing, FENC was trading at $7.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $266.3M. The 52-week trading range was $4.68 to $9.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.